| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4450878
Max Phase: Preclinical
Molecular Formula: C21H21N5O4S2
Molecular Weight: 471.56
Molecule Type: Unknown
Associated Items:
Representations
Canonical SMILES: COc1cc2nc(Nc3cccc(S(N)(=O)=O)c3)nc(NCc3cccs3)c2cc1OC
Standard InChI: InChI=1S/C21H21N5O4S2/c1-29-18-10-16-17(11-19(18)30-2)25-21(26-20(16)23-12-14-6-4-8-31-14)24-13-5-3-7-15(9-13)32(22,27)28/h3-11H,12H2,1-2H3,(H2,22,27,28)(H2,23,24,25,26)
Standard InChI Key: GSMZVFVZMXTCLL-UHFFFAOYSA-N
Associated Targets(non-human)
Pde5a Phosphodiesterase 5A (129 Activities)
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 471.56 | Molecular Weight (Monoisotopic): 471.1035 | AlogP: 3.71 | #Rotatable Bonds: 8 |
| Polar Surface Area: 128.46 | Molecular Species: NEUTRAL | HBA: 9 | HBD: 3 |
| #RO5 Violations: 0 | HBA (Lipinski): 9 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: 10.24 | CX Basic pKa: 5.38 | CX LogP: 3.54 | CX LogD: 3.53 |
| Aromatic Rings: 4 | Heavy Atoms: 32 | QED Weighted: 0.35 | Np Likeness Score: -1.93 |
References
| 1. Pobsuk N, Paracha TU, Chaichamnong N, Salaloy N, Suphakun P, Hannongbua S, Choowongkomon K, Pekthong D, Chootip K, Ingkaninan K, Gleeson MP.. (2019) Design, synthesis and evaluation of N2,N4-diaminoquinazoline based inhibitors of phosphodiesterase type 5., 29 (2): [PMID:30509781] [10.1016/j.bmcl.2018.11.043] |
Source
Source(1):